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A B S T R A C T
The present study investigates the eﬀect of commonly used negative and positive allosteric modulators of the
calcium-sensing receptor (CaSR) on vascular reactivity. In wire myography studies, increasing [Ca2+]o from
1 mM to 6 mM induced concentration-dependent relaxations of methoxamine-induced pre-contracted rabbit
mesenteric arteries, with 6 mM [Ca2+]o producing almost complete relaxation. [Ca
2+]o-induced relaxations were
attenuated in the presence of the calcilytics Calhex-231 and NPS 2143, and abolished by the removal of the
endothelium. In addition to their calcilytic eﬀects, Calhex-231 and NPS 2143 also produced concentration-
dependent inhibitions of methoxamine- or KCl-induced precontracted tone, which were unaﬀected by removal
of the endothelium and unopposed in the presence of the calcimimetic Calindol. In vessels with depleted Ca2+
stores, contractions mediated by Ca2+ inﬂux via voltage-gated Ca2+ channels (VGCCs) were inhibited by
Calhex231. In freshly isolated single rabbit mesenteric artery smooth muscle cells, Calhex-231 and NPS 2143
inhibited whole-cell VGCC currents. Application of Calindol also inhibited methoxamine- and KCl-induced pre-
contracted tone, and inhibited whole-cell VGCC currents. In conclusion, in addition to their CaSR-mediated
actions in the vasculature, Calhex-231, NPS 2143 and Calindol reduce vascular contractility via direct inhibition
of VGCCs.
1. Introduction
The extracellular calcium-sensing receptor (CaSR) has a well-
characterised role in regulating plasma Ca2+ homeostasis through
regulating the secretion of parathyroid hormone (PTH) from the
parathyroid gland. (Brown and MacLeod, 2001; Hofer and Brown,
2003; Ward and Riccardi, 2012). The CaSR is a therapeutic target for
diseases linked to calcium homeostasis, and a series of allosteric
modulators of the CaSR are available (Hebert, 2006; Jensen and
Bräuner-Osborne, 2007; Mancilla and De Luca, 1998; Nemeth et al.,
2001; Petrel et al., 2003; Steddon and Cunningham, 2005). Positive
CaSR modulators such as Cinacalcet and Calindol, termed calcimi-
metics, potentiate the action of extracellular Ca2+ at the receptor to
suppress PTH release (Hebert, 2006; Jensen and Bräuner-Osborne,
2007; Steddon and Cunningham, 2005). As such, Cinacalcet
(Mimpara®), the only allosteric modulator of Gprotein coupled recep-
tors currently approved for clinical use, is used to treat uraemic
secondary hypercalcaemia, and hyperparathyroidism, associated with
parathyroid malignancy (Hebert, 2006; Jensen and Bräuner-Osborne,
2007; Steddon and Cunningham, 2005). Conversely, negative CaSR
modulators such as NPS 2143 and Calhex-231, termed calcilytics,
decrease stimulation of CaSRs to increase PTH release (Mancilla and
De Luca, 1998; Nemeth et al., 2001; Petrel et al., 2003; Steddon and
Cunningham, 2005). Calcilytics have been proposed to treat patients
with gain-of-function CaSR-mutations, and osteoporosis as increases in
plasma PTH levels may have anabolic eﬀects on trabecular and
compact bone (Fitzpatrick et al., 2011; Han and Wan, 2012).
Functional CaSR expression has also been demonstrated in tissues
not associated with regulating calcium homeostasis, including the
vasculature. Stimulation of endothelial CaSRs by increasing the
external Ca2+ concentration ([Ca2+]o) and with calcimimetics induces
nitric oxide (NO) production which leads to vasorelaxations through
stimulation of BKCa channels in vascular smooth muscle cells (VSMCs)
(Awumey et al., 2013; Greenberg et al., 2016; Loot et al., 2013;
Smajilovic et al., 2007; Ziegelstein et al., 2006). Endothelial CaSR
stimulation also activates IKCa channels to induce endothelium-derived
hyperpolarisations (EDH) and vasorelaxations (Awumey et al., 2013;
Dora et al., 2008; Greenberg et al., 2016; Weston et al., 2005, 2008). In
addition, stimulation of CaSRs expressed on perivascular neurons
(Bukoski et al., 1997, 2002; Ishioka and Bukoski, 1999;
Mupanomunda et al., 1998; Wang and Bukoski, 1998) and VSMCs
(Li et al., 2011; Molostvov et al., 2008, 2007; Schepelmann et al., 2016;
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Smajilovic et al., 2006; Wonneberger et al., 2000) have also been linked
to changes in vascular reactivity.
These ﬁndings indicate that calcimimetics and calcilytics may
represent potential therapeutic targets to control vascular contractility.
However, the mechanism of action of these agents on vascular tone is
unclear, with both CaSR-dependent and -independent eﬀects described
(Bonomini et al., 2012; Loot et al., 2013; Rybczynska et al., 2006a,b,
2010; Smajilovic et al., 2007; Thakore and Ho, 2011). Calcimimetics
have been shown to directly induce NO production in endothelial cells
(ECs) and directly inhibit voltage-gated Ca2+ channels (VGCCs) in
VSMCs (Bonomini et al., 2012; Thakore and Ho, 2011). Calcilytics have
also been proposed to attenuate phenylephrine- and KCl-evoked
contractions in mouse aorta and induce an acute hypertensive eﬀect
in vivo studies that may involve a CaSR-dependent or independent
action on the vasculature (Loot et al., 2013; Rybczynska et al., 2006a,b,
2010).
Our limited understanding of the eﬀects of CaSR modulators in the
vasculature is an important omission if the CaSR is to become a
potential therapeutic target to control vascular contractility. In addi-
tion, understanding how these agents aﬀect the vasculature may
predict potential adverse eﬀects of CaSR-related drugs used to regulate
PTH secretion and Ca2+ homeostasis. The present study addresses
these issues by examining how the commonly used CaSR calcilytics,
Calhex-231 and NPS 2143 aﬀect vascular contractility at concentra-
tions which have previously been shown to inhibit CaSR responses in a
variety of tissues. The eﬀects of the calcimimetic compound calindol on
vascular reactivity are also examined. Our results reveal that in
addition to regulating CaSR-mediated changes in vascular tone, these
drugs also inhibit vascular reactivity via CaSR-independent mechan-
isms which predominantly arises from direct blockade of VGCCs.
Importantly, both the CaSR-dependent and independent actions are
likely to occur at similar concentrations.
2. Materials and methods
2.1. Cell and vessel segment preparation
Male New Zealand White rabbits (2.5–3 kg) were killed by intra-
venous injection of sodium pentobarbitone (120 mg/kg) in accordance
with Schedule I of the UK Animals Scientiﬁc Procedures Act, 1986.
Second-order branches of rabbit superior mesenteric artery were
dissected and cleaned of adherent tissue in physiological salt solution
(PSS) containing (mM): NaCl 126, KCl 6, Glucose 10, HEPES 11,
MgCl2 1.2, and CaCl2 1.5, with pH adjusted to 7.2 with 10 M NaOH.
Following dissection, vessels were either cut into 2 mm segments for
wire myography studies or enzymatically dispersed to obtain freshly
isolated single VSMCs. To isolate VSMCs, the vessels were cut open
longitudinally and the endothelium was gently removed from the vessel
wall with a cotton bud, and vessels were then washed in PSS containing
50 µm [Ca2+]o for 5 min at 37 °C and placed in fresh 50 µm [Ca
2+]o PSS
containing collagenase (1 mg/ml) and protease (0.2 mg/ml) for 15 min
at 37 °C. Following this, vessels were triturated in fresh PSS and the
cell-containing solution was collected and centrifuged for 1 min at
1000 rpm. The supernatant was removed and the cells re-suspended in
fresh PSS containing 0.75 mM [Ca2+]o, plated onto coverslips, and left
at 4 °C for 1 h before use.
2.2. Isometric tension recordings
The eﬀects of increasing concentrations of [Ca2+]o, Calhex-231,
NPS 2143 and Calindol on vascular tone were investigated using wire
myography. Vessel segments of 2 mm in length were mounted in a wire
myograph (Model 610 M; Danish Myo Technology, Aarhus, Denmark)
and equilibrated for 30 min at 37 °C in 5 ml of gassed (95% O2/5%
CO2) Krebs– Henseleit solution of the following composition (mM):
NaCl 118, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, CaCl2 1, D-
glucose 10. The mean resting diameter of the vessel segments was 402
± 6 µm (n=32 animals, 122 vessel segments, ± S.E.M). Once mounted,
vessel segments were then normalized to 90% of the internal circum-
ference predicted to occur under a transmural pressure of 100 mmHg
(Mulvany and Halpern, 1977). Mean resting vessel tension following
normalisation was 5.6 ± 0.1 mN (n=32 animals, 122 vessel segments,
± S.E.M). Vessels were left for 10 min and were then challenged with
60 mM KCl for 5 min before being washed out with fresh Krebs
solution. Endothelium integrity was then assessed by stably pre-
contracting vessels with the α1 adrenoceptor agonist 10 µm methox-
amine (the concentration which gives 80% of the maximal methox-
amine-induced response) followed by the addition of 10 µm Carbachol
(CCh). Vessels in which CCh-induced relaxations were > 90% of pre-
contracted tone were designated as having a functional endothelium.
When necessary, endothelium was removed by rubbing the intima with
a human hair, and CCh-induced relaxations of < 10% of pre-contracted
arteries indicated successful removal. Vessel segments were incubated
for 30 min in fresh Krebs solution and then pre-contracted with 10 µm
methoxamine or 60 mM KCl as required. This was followed by
cumulative additions of CaCl2, Calhex-231 (4-Chloro-N-[(1 S,2 S)−2-
[[(1 R)−1-(1naphthalenyl)ethyl]amino]cyclohexyl]-benzamide
Hydrochloride), NPS 2143 (2-Chloro-6[(2 R)−3-[[1,1-dimethyl-2-(2-
naphthalenyl)ethyl]amino-2-hydroxypropoxy]benzonitrile
Hydrochloride), Calindol (N-[(1 R)−1-(1-Naphthalenyl)ethyl]−1H-in-
dole-2-methanamine Hydrochloride; (R)−2-[[[1-(1-Naphthyl)ethyl]
amino]methyl]−1H-indole Hydrochloride) or their respective vehicles.
When required, inhibitors were added to the vessel segments 30 min
before the construction of the concentration-response curves and were
present throughout the experiments after this initial exposure period.
Experiments carried out in the presence of an inhibitor following an
initial 30 min exposure period are described throughout as performed
‘in the presence of’ the relevant inhibitor tested.
In a separate set of experiments, the inhibitory eﬀects of Calhex-
231 on vascular contractility mediated by Ca2+ inﬂux through activa-
tion of VGCCs was examined in endothelium removed vessels following
depletion of intracellular Ca2+ stores. Vessels were equilibrated in
Krebs solution containing 0 mM [Ca2+]o, and the cell-permeable Ca
2+
chelator BAPTA-AM (50 µm) was added to the bath followed by a series
of 10 µm methoxamine additions until no contractile response was
observed. Vessels were then washed in fresh Ca2+-free Krebs solution
together with 3 µm or 10 µm Calhex-231, or its vehicle dimethyl
sulfoxide (DMSO) and left for 30 mins. This was followed by the
addition of 10 µm methoxamine, and after 3 mins, 2 mM [Ca2+]o was
added to the bath.
For each experiment described above, controls were performed
using vessel segments isolated from the same animal. All relaxant
responses are expressed as percentage relaxation of pre-contracted
tone induced by either 10 µm methoxamine or 60 mM KCl. In the Ca2+
inﬂux experiment, contractions are expressed as a percentage of the
maximum contraction induced by 2 mM [Ca2+]o following stimulation
with 10 µm methoxamine, in the absence of any drug or vehicle
(DMSO). Control vessels also had their calcium stores depleted and
were lacking a functional endothelium. Data points on all graphs and
bars on all bar charts are mean values and error bars represent S.E.M.
For each experiment n=number of animals, with at least 3–4 vessel
segments used from each animal.
Responses were analysed by 2-Way ANOVA followed by Bonferroni
post hoc tests or by Student's t-test where appropriate. Where required,
drug concentrations inhibiting 50% of the contraction (IC50) as well as
the maximal inhibition (Emax) were calculated from an inspection of the
dose-response curves and compared using Student's t-test. In all
analyses, P < 0.05 was taken as statistically signiﬁcant. Bonferroni
comparisons are shown above the graph data points whereby: *P <
0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. controls. Statistical
analyses and graphs were made using Graphpad Prism 6 software
(GraphPad Software, Inc, San Diego, CA, USA).
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2.3. Electrophysiology
The whole-cell conﬁguration of the patch clamp technique was used
to record VGCC currents. In voltage–clamp mode, currents were
evoked by a single depolarising step from a holding potential of
−70 mV to +20 mV for a duration of 350 ms. In these experiments
barium was used as the charge carrier, as barium is more permeant
than Ca2+ through VGCCs and reduces Ca2+-induced inactivation. The
external bath solution contained (mM): BaCl2 110, HEPES 10, Glucose
11, TEA 10 (pH adjusted to 7.4 with Ba(OH)2). The pipette solution
contained (mM): Cesium glutamate 140, EGTA 10, MgCl2 2.5, MgATP
2.5, with pH adjusted to 7.4 with CsOH. Recordings were made with an
Axopatch 200B ampliﬁer (Axon Instruments, Union City, CA, USA) at
room temperature (20–23 °C). Currents were ﬁltered at 1 kHz (−3 dB,
low-pass 8-pole Bessel ﬁlter, Frequency Devices model LP02; Scensys,
Aylesbury, UK) and sampled at 5 kHz (Digidata 1322 A and pCLAMP
9.0 software; Molecular Devices, Sunnydale, CA, USA). Data from n=7
patches and at least 3 animals were analysed using paired Student's t-
test with P < 0.05 considered signiﬁcant. Figures and analyses were
made using MicroCal Origin 6.0 software (MicroCal Software,
Northampton, MA, USA).
2.4. Materials
All materials were purchased from Sigma-Aldrich (Sigma Chemical
Co., Poole, UK) or Tocris (Tocris Biosciences, Bristol, UK). Drugs were
dissolved in distilled water or DMSO.
3. Results
3.1. Calhex-231 and NPS 2143 inhibit both CaSR-mediated
vasorelaxations and peak amplitudes of methoxamine pre-contracted
rabbit mesenteric arteries
We initially performed wire myography studies to conﬁrm that
stimulation of endothelium CaSRs induced vasorelaxations of pre-
contracted rabbit mesenteric arteries (Greenberg et al., 2016).
Fig. 1A(i), (ii) and B show that increasing [Ca2+]o from 1 mM to
6 mM induced concentration-dependent vasorelaxations of methoxa-
mine pre-contracted arteries compared to vehicle controls, with 6 mM
[Ca2+]o inducing almost complete relaxation. To conﬁrm that [Ca
2+]o-
induced vasorelaxations were mediated by stimulation of CaSRs, vessel
segments were pre-treated with the calcilytics Calhex-231 and NPS
2143 at concentrations commonly used to study CaSR responses
(Faure et al., 2009; Johansson et al., 2013; Nemeth et al., 2001;
Petrel et al., 2003, 2004; Saidak et al., 2009; Yamamura et al., 2012,
2013, 2015). Fig. 1A(iii) and B show that [Ca2+]o-induced relaxations
were signiﬁcantly attenuated in the presence of 3 µm Calhex-231 and
1 µm NPS 2143, whereas 1 µm Calhex231 had no eﬀect. Moreover,
Fig. 1A(iv) and B also demonstrate that removal of the endothelium
abolished [Ca2+]o-induced vasorelaxations. These ﬁndings conﬁrm that
stimulation of CaSRs induces endothelium-dependent vasorelaxations
of pre-contracted arteries as previously described (Awumey et al.,
2013; Greenberg et al., 2016; Weston et al., 2005, 2008).
Intriguingly, Fig. 1A(iii) and C also identify that the peak amplitude
of the methoxamine induced vasoconstrictions was signiﬁcantly atte-
nuated in the presence of 1 µm, 3 µm, and 10 µm Calhex-231 in a
concentration-dependent manner, and by 1 µm NPS 2143. This
observation suggests that either CaSRs are involved in augmenting
methoxamine-induced vasoconstrictions or that these calcilytics inhibit
vascular reactivity via CaSR-independent mechanisms. Importantly,
these results indicate that the negative eﬀects of these calcilytics on
vascular reactivity occur at similar concentrations to those required to
reduce [Ca2+]o induced relaxations.
3.2. Calhex-231 evokes vasorelaxations of methoxamine- and KCl-
induced precontracted tone via CaSR-independent mechanisms
To investigate the potential CaSR-dependent and -independent
eﬀects of calcilytics on vascular contractility, we studied the action of
Calhex-231 on methoxamine- and KCl- precontracted arteries.
Methoxamine- and KCl-induced contractions are greatly reduced by
VGCC blockers indicating that these contractions are primarily
mediated by Ca2+ inﬂux via activation of VGCCs (Supplementary
Fig. 1). 60 mM KCl also clamps the membrane potential of vessels at
about −20 mV which prevents hyperpolarisation-mediated mechan-
isms that are associated with CaSR-mediated vasorelaxations
(Greenberg et al., 2016; Weston et al., 2005, 2008).
In vessels containing a functional endothelium, Fig. 2A(i), (ii), B
and Table 1 show that Calhex-231 evoked concentration-dependent
inhibitions of both methoxamine- and KCl induced pre-contracted
tone, with similar IC50 values and Emax values about 2 µm and 98%
respectively. To establish whether endothelial CaSRs were involved in
mediating the inhibitory responses to Calhex-231, we repeated these
experiments in vessels lacking a functional endothelium. Fig. 2C and
Table 1 show that removing the endothelium had no eﬀect on IC50 or
Emax values of the inhibitory eﬀects of Calhex-231 on methoxamine- or
KCl induced pre-contracted tone. In vehicle control experiments,
DMSO had no eﬀect on either methoxamine or KCl-evoked pre-
contracted tone (data not shown). We also hypothesised that if
CaSRs were involved in mediating inhibitions of pre-contracted tone
by Calhex-231 then these eﬀects may be opposed by the calcimimetic
Calindol. Fig. 2D and Table 1 show that pre-treating vessels with
Calindol, at a concentration known to stimulate CaSRs (Faure et al.,
2009; Petrel et al., 2004; Thakore and Ho, 2011) did not aﬀect the
inhibitory eﬀect of Calhex-231 on methoxamine-induced pre-con-
tracted tone.
Taken together, these ﬁndings therefore indicate that the inhibitory
action of Calhex-231 on methoxamine- or KCl- pre-contracted arteries
are unlikely to be mediated by CaSRs.
3.3. Calhex-231 inhibits extracellular Ca2+-inﬂux via VGCCs in store-
depleted vessels
Since both methoxamine- and KCl-evoked vasoconstrictions are
predominantly dependent on activation of VGCCs (Supplementary
Fig. 1), we thought that the CaSR-independent reduction of pre-
contracted tone by Calhex-231 may be via inhibition of these channels.
To investigate this idea further, we examined the eﬀect of Calhex-231
on vascular contractility using a protocol in which agonist-evoked
vascular tone is driven by Ca2+ inﬂux through activation of VGCCs, and
is unlikely to involve release of Ca2+ from internal Ca2+ stores (Thakore
and Ho, 2011). Fig. 3A shows that vessel segments lacking a functional
endothelium were equilibrated in 0 mM [Ca2+]o Krebs solution to
prevent Ca2+ inﬂux, and then BAPTA-AM was applied to deplete Ca2+
stores. In these conditions, methoxamine did not induce contractile
responses, indicating that Ca2+ stores had been successfully depleted.
Fig. 3A and B show that following stimulation with methoxamine,
increasing [Ca2+]o to 2 mM induced stable vasoconstrictions that were
inhibited by the VGCC blocker nicardipine (~100% inhibition) and by
the presence of 3 µm and 10 µm Calhex-231 by around 40% and 80%
respectively. In vehicle control experiments, the presence of DMSO did
not aﬀect the vasoconstrictions induced by 2 mM [Ca2+]o. These
ﬁndings provide evidence that Calhex-231 inhibits agonist-induced
vasoconstrictions via inhibition of VGCCs.
3.4. Calhex-231 inhibits VGCCs
To provide more direct evidence that Calhex-231 inhibits VGCCs,
we investigated the eﬀect of this calcilytic on VGCC currents from
freshly isolated single rabbit mesenteric artery VSMCs using whole-cell
H.Z.E. Greenberg et al. European Journal of Pharmacology 791 (2016) 659–668
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patch clamp recordings. Fig. 4A and C show that application of
depolarising steps from a holding potential of −70 mV to +20 mV for
a duration of 350msec elicited whole-cell inward currents, which
reached peak amplitude after about 10-20msec before decaying slightly
to a sustained level and were inhibited by nicardipine. There was no
indication of background currents being sensitive to nicardipine at the
holding potential which suggests that these whole-cell VGCC currents
were activated by the applied voltage steps. In time-control experi-
ments, there was no signiﬁcant decrease in the peak amplitude of
inward currents following repeated depolarising steps every 20 s for
2 min (data not shown). Fig. 4 shows that bath application of 1, 3 and
10 µm Calhex-231 signiﬁcantly inhibited mean VGCC current densities
by about 25%, 60% and 95% respectively. Fig. 4C also reveals that
inhibitions of VGCC currents by 3 µm Calhex-231 were unaﬀected by
the presence of 1 µm Calindol.
3.5. NPS 2143 also induces vasorelaxations by inhibiting VGCCs
In our next series of experiments, we investigated whether the
inhibitory action of NPS 2143 on agonist-evoked contractions observed
earlier (see Fig. 1) also resulted from inhibition of VGCCs. Fig. 5A and
Table 1 show that NPS 2143 induced a concentration-dependent
inhibition of methoxamine-induced pre-contracted tone lacking a
functional endothelium, with IC50 and Emax values of about 3 µm and
99% respectively. Fig. 5A and Table 1 also show that NPS 2143
inhibited KCl-induced pre-contracted tone. However, NPS 2143 was
signiﬁcantly less potent at inhibiting KCl-induced pre-contracted tone
(IC50 and Emax values of about 13 µm and 80% respectively) compared
to methoxamine-induced precontracted tone. Finally, Fig. 5B and C
show that 1 µm and 10 µm NPS 2143 inhibited whole-cell VGCC
currents by about 30% and 75% respectively.
Taken together, these ﬁndings strongly indicate that, similar to
Calhex-231, NPS2143 also reduces vascular tone by directly inhibiting
VGCCs. Importantly the inhibition of vascular reactivity by Calhex-231
and NPS 2143 occurs at concentrations previously shown to reduce
CaSR-mediated responses in other cell and tissue types, with IC50
values of ~0.4 µm reported for both of these compounds, and max-
imum inhibition of CaSR responses achieved between ~3–10 µm
(Faure et al., 2009; Jensen and Bräuner-Osborne, 2007; Johansson
et al., 2013; Nemeth et al., 2001; Petrel et al., 2004, 2003; Saidak et al.,
2009; Yamamura et al., 2015).
3.6. Calindol induces vasorelaxations by inhibiting VGCCs
In our ﬁnal experiments, we investigated the vascular actions of the
calcimimetic Calindol on methoxamine- and KCl-induced pre-con-
tracted arteries, and whole-cell VGCC currents. Fig. 6A, B and
Table 1 show that Calindol evoked concentration-dependent inhibi-
tions of methoxamine- and KCl-induced pre-contracted tone which
were unaﬀected by removal of the endothelium. In addition, Fig. 6C
shows that the presence of 3 µm Calhex-231 had little eﬀect on these
inhibitory actions of Calindol. Moreover, Fig. 6D shows that 1 µm and
10 µm Calindol signiﬁcantly inhibited mean VGCC current densities
by about 30% and 80%. These ﬁndings provide strong evidence that,
Fig. 1. Eﬀect of CaSR stimulation and calcilytics on pre-contracted rabbit mesenteric arteries. (A) Representative traces showing the eﬀect of increasing [Ca2+]o on pre-contracted
arteries induced by 10 µm methoxamine (MO). Record (i) shows that MO induces a stable vasoconstriction in the presence of 1 mM [Ca2+]o, and the eﬀect of adding increasing volumes
of distilled H2O to the myograph bath. Record (ii) shows the eﬀect of increasing [Ca
2+]o from 1 mM to 6 mM. Record (iii) shows that the presence of Calhex-231, inhibits both [Ca
2+]o-
induced vasorelaxations and amplitude of methoxamine-induced vasoconstriction. Record (iv) demonstrates the eﬀect of removing the endothelium on Ca2+]o-induced vasorelaxations.
(B) Mean data showing that [Ca2+]o-induced vasorelaxations are attenuated in the presence of 3 µm Calhex-231, 1 µm NPS 2143, and removal of the endothelium. 1 µm Calhex-231
however is without eﬀect. **P < 0.01, ***P < 0.001, ****P < 0.0001, 2-way ANOVA followed by Bonferroni post hoc test. (C) Mean data showing the eﬀect of 1, 3 and 10 µm Calhex-231
or 1 µm NPS 2143 on mean amplitude of the methoxamine-induced pre-contracted arteries. Each point is from n=4 animals, with at least n=3 vessel segments per animal. Student's t-
test, **P < 0.01.
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similar to the calcilytics Calhex-231 and NPS 2143, Calindol inhibits
pre-contracted arteries independently of the CaSR by directly inhibit-
ing VGCCs at concentrations commonly used to stimulate CaSR-
mediated responses (EC50 ~1 µm) (Jensen and Bräuner-Osborne,
2007; Nemeth et al., 1998; Petrel et al., 2004; Saidak et al., 2009;
Thakore and Ho, 2011).
4. Discussion
The present study demonstrates that the calcilytics Calhex-231 and
NPS 2143, regulate vascular tone in rabbit mesenteric arteries via two
distinct pathways; they modulate CaSRs involved in producing en-
dothelium-dependent vasorelaxations, and inhibit agonist-evoked con-
tractions by directly blocking VGCCs. These CaSR-independent eﬀects
of calcilytics on vascular reactivity are novel ﬁndings, which may have
important implications for the use of these CaSR modulators in
treating disease. In addition, the present study demonstrates that the
calcimimetic Calindol also inhibits VGCCs, providing further insight
into the known CaSR-independent actions of this compound.
4.1. Calhex-231 and NPS 2143 regulate pre-contracted arteries via
CaSR-dependent and -independent pathways
In the vasculature, CaSRs are expressed in ECs, VSMCs, and
perivascular neurones, and stimulation of these receptors has been
linked to vasoconstrictions and vasorelaxations (Bukoski et al., 1997;
Greenberg et al., 2016; Schepelmann et al., 2016; Weston et al., 2005;
Ziegelstein et al., 2006). In the present study, increasing [Ca2+]o from
1 mM to 6 mM evoked dose-dependent vasorelaxations of pre-con-
tracted rabbit mesenteric arteries which were signiﬁcantly inhibited by
Calhex-231 and NPS 2143, and abolished by the removal of the
endothelium. These ﬁndings are in agreement with several studies
showing that stimulation of endothelial CaSRs induces NO- and EDH-
mediated vasorelaxations of precontracted arteries (Awumey et al.,
2013; Dora et al., 2008; Greenberg et al., 2016; Weston et al., 2005,
2008).
The current work revealed the surprise ﬁndings that applications of
the calcilytics Calhex231 and NPS 2143 markedly inhibited methox-
amine- and KCl-induced pre-contracted tone. In investigating these
responses further, we determined four points of evidence which
indicate that Calhex-231 and NPS 2143 regulate vascular reactivity
via CaSR-independent mechanisms. First, the present work shows that
stimulation of CaSRs evokes vasorelaxations of methoxamine pre-
contracted arteries, and therefore calcilytics acting at CaSRs would
not be expected to produce similar actions. Secondly, previous data
showed that stimulation of CaSRs by increasing [Ca2+]o did not aﬀect
KCl-induced contractions, implying that CaSR-mediated vasorelaxa-
tions are produced by hyperpolarisations, which are prevented by
Fig. 2. Eﬀect of Calhex-231 on pre-contracted arteries. (A) Representative traces showing the eﬀect of increasing concentrations of Calhex-231 on pre-contracted tone induced by 10 µm
methoxamine (i) or 60 mM KCl (ii). Mean data showing the eﬀect of Calhex-231 on precontracted endothelium-intact (B) and endothelium-removed (C) rabbit mesenteric arteries.
Removal of the endothelium did not attenuate the Calhex-231-induced responses on either methoxamine- or KCl-induced pre-contracted arteries. (D) Mean data in endothelium-intact
vessels showing that the presence of 1 µm Calindol also did not aﬀect Calhex-231-induced responses on methoxamine-induced pre-contracted arteries. Each point is from n=4 animals,
with at least n=3 vessel segments per animal.
H.Z.E. Greenberg et al. European Journal of Pharmacology 791 (2016) 659–668
663
60 mM external KCl that clamps the membrane potential of vessels at
about −20 mV. However, we show that KCl-induced contractions were
inhibited by Calhex-231 and NPS 2143, which suggests that these
calcilytics are likely acting via diﬀerent mechanisms to those produced
by stimulation of CaSRs. Thirdly, we show that removing the endothe-
lium abolishes the inﬂuence of endothelial CaSRs on vascular tone, but
Calhex231 and NPS 2143 reduced pre-contracted tone in the absence
of a functional endothelium. Finally, the calcimimetic Calindol may be
expected to oppose the inhibitory actions of Calhex-231 on vascular
tone if this eﬀect was mediated by CaSRs. However, reduction of
vascular tone by Calhex-231 was maintained in the presence of
Calindol.
Taken together, these results support the conclusion that Calhex-
231 and NPS 2143 have an inhibitory eﬀect on vascular contractility via
a CaSR-independent mechanism.
4.2. CaSR-independent actions of Calhex-231, NPS 2143, and
Calindol on precontracted arteries are through inhibition of VGCCs
Methoxamine- and KCl-evoked pre-contracted tone measured using
wire myography are almost completely inhibited by VGCC blockers,
and therefore these contractions are likely to be predominantly
mediated by Ca2+ inﬂux produced by activation of VGCCs. We therefore
hypothesised that the CaSR-independent inhibitory actions of Calhex-
231 and NPS 2143 on vascular tone may result from direct inhibition of
VGCCs. In support of this hypothesis, we observed that in vessels with
depleted Ca2+ stores, Calhex-231 signiﬁcantly impaired [Ca2+]o-in-
duced vasoconstrictions mediated via Ca2+ inﬂux through activation of
VGCCs. Moreover, Calhex-231 inhibited whole-cell VGCC currents in
freshly isolated single rabbit mesenteric artery VSMCs, an eﬀect that
was unopposed by the presence of calindol and NPS 2143 likewise
inhibited whole-cell VGCC currents, providing the most direct evidence
so far that these calcilytics act as VGCC blockers.
Interestingly, NPS 2143 was signiﬁcantly more potent at inhibiting
methoxamine-induced contractions compared to KCl-evoked re-
sponses. The precise reason for this is unclear, but may suggest that
part of the NPS 2143 inhibition of methoxamine-induced contractions
involves VSMC membrane hyperpolarisations.
The present study also provides similar evidence for the calcimi-
metic Calindol modulating vascular tone through a CaSR-independent
inhibition of VGCCs. Calindol inhibited methoxamine- and KCl-in-
duced pre-contracted tone in a concentration-dependent manner,
which was insensitive to removal of the endothelium. The actions of
Calindol on vascular reactivity were also unaﬀected by the presence of
Calhex-231, which would be expected to oppose the actions of Calindol
if they were mediated via the CaSR. Moreover, Calindol inhibited
Table 1
The effect of the various modulators tested on pre-contracted rabbit mesenteric arteries.
Data are presented as mean values ± SEM. IC50 and Emax values were compared with
using Student's t-test. n=4 animals used for each experiment, with at least 3 vessel
segments per animal.
Calhex-231 on 10 µM Methoxamine pre-contracted tone
IC50 (µM) Emax (%)
+Endothelium 2.01 ± 0.61 96.2 ± 2.3
−Endothelium 2.00 ± 0.27 94.4 ± 3.1
+1 µM Calindol 2.08 ± 0.19 92 ± 5.4
Calhex−231 on 60 mM KCl pre-contracted tone
+Endothelium 1.93 ± 0.40 98 ± 1.5
−Endothelium 2.02 ± 0.23 97.1 ± 2.2
NPS 2143 on - Endothelium pre-contracted vessels
Methoxamine 2.97 ± 0.34 99.1 ± 3.2
KCl 12.5 ± 0.73a 78.4 ± 3.4a
Calindol on 10 µM Methoxamine pre-contracted tone
+Endothelium 2.06 ± 0.24 96.48 ± 1.4
−Endothelium 2.66 ± 0.30 94.4 ± 2.8
+3 µM Calhex−231 2.58 ± 0.35 97.2 ± 1.1
Calindol on 60 mM KCl pre-contracted tone
+Endothelium 3.26 ± 0.24b 82.2 ± 2.3b
−Endothelium 3.41 ± 0.32c 83.4 ± 1.6c
a P < 0.05 vs. the eﬀect of NPS 2143 on 10 µm Methoxamine pre-contracted tone.
b P < 0.05 vs. the eﬀect of calindol on 10 µm Methoxamine precontracted tone in
vessels with a functional endothelium (+endothelium).
c P < 0.01 vs. the eﬀect of calindol on 10 µm Methoxamine precontracted tone in
vessels lacking a functional endothelium (−endothelium).
Fig. 3. Eﬀect of Calhex-231 on contractions induced by Ca2+ inﬂux via activation of VGCCs. (A) Representative trace and (B) mean data showing that in endothelium-removed vessels
with depleted Ca2+ stores, Calhex-231, but not it's vehicle DMSO, inhibits contractions induced by the addition of 2 mM [Ca2+]o following stimulation with methoxamine (see text for
experimental detail). n=4 animals, with at least n=3 vessel segments per animal, Student’s t-test, **P < 0.01, ****P < 0.0001. Contractions are expressed as % of the maximum
contraction induced by the addition of 2 mM [Ca2+]o following stimulation with methoxamine in endothelium-denuded control vessels with depleted Ca
2+ stores, in the absence of
Calhex-231 or DMSO.
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whole-cell VGCC currents in VSMCs. Together, these ﬁndings support
earlier ﬁndings proposing that Calindol inhibits VGCCs to reduce
agonist-evoked contractions (Thakore and Ho, 2011).
4.3. Signiﬁcance of results in relation to functional studies
Our results indicate that the CaSR-independent eﬀects of Calhex-
231, NPS 2143, and Calindol occur at concentrations considered
appropriate for studying CaSR responses (Nemeth et al., 1998, 2001;
Petrel et al., 2003, 2004). Importantly, CaSR-independent reduction of
pre-contracted tone and VGCC currents by Calhex-231 also occurred at
1 µm, a concentration that had no eﬀect on CaSR-mediated vasor-
elaxations (Figs. 1 and 4). Moreover, at 300 nM Calhex-231, signiﬁcant
calindol-insensitive impairment of both KCl and methoxamine con-
tractions was also observed (Fig. 2). Taken together, this suggests that
there is unlikely to be diﬀering concentration windows for the CaSR-
Fig. 4. Eﬀect of Calhex-231 on VGCC activity. (A) Representative trace showing that the VGCC blocker nicardipine inhibited whole-cell inward currents activated by a single
depolarising step from a holding potential of −70 mV to +20 mV for a duration of 350msecs in a freshly isolated single rabbit mesenteric artery VSMC. (B) Representative trace and (C)
bar graph of mean data showing that Calhex-231 inhibited whole-cell VGCC currents in a concentration-dependent manner. Inhibitions of VGCC currents by 3 µm Calhex-231 were
unopposed by Calindol. For each experiment, currents were recorded from 7 patches from n=3–4 animals. **P < 0.01, ****P < 0.0001, Student's t-test.
Fig. 5. Eﬀect of NPS 2143 on pre-contracted tone and VGCC activity. (A) Mean data showing that NPS 2143 induced vasorelaxations of methoxamine-induced pre-contracted
endothelium removed vessels. Note that NPS 2143-induced vasorelaxations of KCl-induced contractions are attenuated compared to the eﬀects on methoxamine-induced contractions.
n=4 animals used per experiment, n=3 vessel segments per animal. **P < 0.01, ***P < 0.001, ****P < 0.0001, 2-way ANOVA followed by Bonferroni post hoc test. (B) Representative
trace and (C)mean data showing that increasing concentrations of NPS 2143 inhibited whole-cell VGCC currents. n=7 patches from n=4 animals. **P < 0.01, ****P < 0.0001, Student's t-
test.
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dependent and independent actions of the agents used in this study.
This conclusion has important implications when evaluating functional
studies investigating the role of CaSRs in the vasculature, and also in
other cells which express VGCCs.
In previous studies, inhibitory eﬀects of calcilytics on agonist-
evoked pre-contracted tone have been interpreted as CaSRs having an
important role in augmenting these responses (Loot et al., 2013;
Yamamura et al., 2016). Likewise, calhex-231 was shown to inhibit
oxytocin-induced contractions of rat uterine tissue, with a role for the
CaSR in augmenting these contractions therefore suggested
(Crankshaw et al., 2013). Our ﬁndings suggest that these observations
may also reﬂect an oﬀ-target inhibitory action of calcilytics at VGCCs.
Nevertheless, vascular smooth muscle speciﬁc CaSR KO mice do
exhibit a small but signiﬁcant reduction in phenylephrine- and KCl-
evoked vasoconstrictions and blood pressure (Schepelmann et al.,
2016). It will be interesting to investigate if calcilytics produce further
reductions in agonist-evoked contractions and blood pressure in these
CaSR KO mice.
Intriguingly, treatment with NPS 2143 has also been shown to
induce an acute increase in arterial pressure of normotensive rats
(Rybczynska et al., 2006a,b, 2010) which is in contrast to the eﬀects
predicted from our ﬁndings. However, this hypertensive eﬀect was only
observed in the presence of parathyroid glands, which may suggest that
the eﬀect of NPS 2143 was due to changes in PTH levels following
CaSR inhibition rather than a direct vascular action. Additionally,
negative modulation of the CaSR has also been proposed to increase
levels of renin, which could account for the acute hypertensive
phenomenon following NPS 2143 administration (Atchison et al.,
2010; Smajilovic et al., 2011).
Our ﬁndings may also signify potential cardiovascular side eﬀects
when using calcilytics in treating diseases such as osteoporosis and
hypocalcaemia from gain-of-function CaSR mutations (Hebert, 2006;
Jensen and Bräuner-Osborne, 2007; Saidak et al., 2009). In addition,
calcilytics have been proposed as a treatment strategy for idiopathic
pulmonary arterial hypertension (IPAH), where CaSR expression is
proposed to up-regulated and involved in proliferation of VSMCs and
increased arterial tone (Li et al., 2011; Yamamura et al., 2012, 2013,
2015, 2016). Our data suggest that these observations might result
from inhibition of VGCCs by calcilytics rather than through CaSR
inhibition. In agreement, several VGCC antagonists have been shown to
inhibit proliferation of VSMCs in IPAH (Rich et al., 1992; Sitbon et al.,
2005). Recently it has also been suggested that calcilytics could be
repurposed for treating asthma, as upregulated CaSR-signalling has
been shown to mediate increased airway hyperresponsiveness in an
asthmatic mouse model and in human lung tissue isolated from
asthmatic patients (Yarova et al., 2015). Potential cardiovascular side
eﬀects when using calcilytics may therefore also be relevant for this
suggestion, and nonspeciﬁc actions of calcilytics on VGCCs may also
Fig. 6. Eﬀect of Calindol on pre-contracted arteries and VGCC activity. (A) and (B) Mean data showing that Calindol induced vasorelaxations of methoxamine-induced pre-contracted
endothelium-intact and endothelium-removed vessels. Note that Calindol-induced vasorelaxations are slightly attenuated when vessels are pre-contracted with 60 mM KCl. (C) Mean
data showing that the presence of 3 µm Calhex has no eﬀect on Calindol-induced relaxations of methoxamine-evoked arteries. **P < 0.01, ***P < 0.001, ***P < 0.001, 2-way ANOVA
followed by Bonferroni post hoc test. (D) Mean data showing that increasing concentrations of Calindol inhibited whole-cell VGCC currents. n=7 patches from n=3–4 animals. ****P <
0.0001.
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partly explain why nebulised calcilytics blunt bronchoconstriction in
the animal model of asthma tested in the study.
Calcimimetic compounds have emerged as valuable therapeutic
agents in the treatment of hyperparathyroidism caused by loss-of-
function CaSR mutations as well as in parathyroid cancer (Hebert,
2006; Jensen and Bräuner-Osborne, 2007; Nemeth et al., 1998; Saidak
et al., 2009). Similar to our ﬁndings with calcilytics, we propose that
caution should be considered when interpreting functional studies
using calcimimetics. Accordingly, it is possible that the chronic
hypotensive eﬀect that follows treatment with calcimimetics in rat
models of renal failure could result from the inhibitory action of these
compounds on VGCCs (Carrasco et al., 2004; Ogata et al., 2003;
Odenwald et al., 2006; Rybczyńska et al., 2005, 2006a,b). This action
may also explain the observation that calcimimetics protect against
arterial calciﬁcation (Alam et al., 2009), as this aﬀect has also been
observed in studies using classical VGCC inhibitors (Chen et al., 2010).
Interestingly, this study reveals that both calycilytic and calcimi-
metic modulators of CaSRs reduced pre-contracted tone by inhibiting
VGCCs. It is likely that molecular similarities account for this, as NPS
2143, Calhex-231, and Calindol are structurally-related to the pheny-
lalkylamines, sharing a positively charged amino group (Jensen and
Bräuner Osborne, 2007; Nemeth et al., 2001, 1998; Petrel et al., 2003;
Saidak et al., 2009). Indeed, the lead compound used in the develop-
ment of calcimimetics such as NPS R-568, Cinacalcet, and Calindol,
was the phenylalkylamine Fenidiline, which is a potent VGCC blocker
that displays weak allosteric potentiation of the CaSR (Jensen and
Bräuner Osborne, 2007; Nemeth et al., 2001, 1998; Petrel et al., 2003;
Saidak et al., 2009). Further screening of a series of compounds based
on the phenylalkylamine structure led to the discovery of NPS 2143,
and the subsequent development of Calhex-231 (Jensen and Bräuner-
Osborne, 2007; Nemeth et al., 2001; Petrel et al., 2003). This structural
similarity is highlighted by the fact that NPS 2143, Calhex-231, NPS R-
568, Cinacalcet, and Calindol all target a common allosteric site within
the seventh transmembrane domain of the CaSR. Calcilytics based on
an unrelated quinazolinone structure have also been developed, namely
ATF936 and AXT914 (John et al., 2014; Letz et al., 2014). In the
future, it will be interesting to investigate if these agents also have
CaSR-dependent and -independent actions in the vasculature, and
whether they inhibit VGCC channels.
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